Core Insights - Genentech, a member of the Roche Group, announced significant results from the Phase III INShore study of Gazyva (obinutuzumab) for treating idiopathic nephrotic syndrome in children and young adults aged 2-25 years [1] Group 1 - The Phase III INShore study met its primary endpoint, demonstrating that more patients achieved sustained complete remission at one year (week 52) with Gazyva compared to mycophenolate mofet [1]